NURR1 Impairment in Multiple Sclerosis.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
30 Sep 2019
Historique:
received: 30 08 2019
revised: 27 09 2019
accepted: 28 09 2019
entrez: 3 10 2019
pubmed: 3 10 2019
medline: 11 2 2020
Statut: epublish

Résumé

The transcription factor NURR1 is a constitutively active orphan receptor belonging to the steroid hormone receptor class NR4A. Although a genetic association between NURR1 and autoimmune inflammatory diseases has never emerged from genome-wide association studies (GWAS), alterations in the expression of NURR1 have been observed in various autoimmune diseases. Specifically, its role in autoimmune inflammatory diseases is mainly related to its capability to counteract inflammation. In fact, NURR1 exerts anti-inflammatory functions inhibiting the transcription of the molecules involved in proinflammatory pathways, not only in the peripheral blood compartment, but also in the cerebral parenchyma acting in microglial cells and astrocytes. In parallel, NURR1 has been also linked to dopamine-associated brain disorders, such as Parkinson's disease (PD) and schizophrenia, since it is involved in the development and in the maintenance of midbrain dopaminergic neurons (mDA). Considering its role in neuro- and systemic inflammatory processes, here we review the evidences supporting its contribution to multiple sclerosis (MS), a chronic inflammatory autoimmune disease affecting the central nervous system (CNS). To date, the specific role of NURR1 in MS is still debated and few authors have studied this topic. Here, we plan to clarify this issue analyzing the reported association between NURR1 and MS in human and murine model studies.

Identifiants

pubmed: 31574937
pii: ijms20194858
doi: 10.3390/ijms20194858
pmc: PMC6801584
pii:
doi:

Substances chimiques

NR4A2 protein, human 0
Nuclear Receptor Subfamily 4, Group A, Member 2 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Nat Commun. 2011;2:269
pubmed: 21468021
Eur J Neurol. 2012 Jun;19(6):870-5
pubmed: 22309633
Inflamm Res. 2015 Nov;64(11):841-4
pubmed: 26337347
Nat Immunol. 2013 Mar;14(3):230-7
pubmed: 23334790
Eur J Immunol. 2016 Aug;46(8):1842-53
pubmed: 27184189
Curr Treat Options Neurol. 2018 Apr 7;20(5):12
pubmed: 29627873
J Neurol Sci. 2011 Dec 15;311(1-2):9-14
pubmed: 21752397
Oncotarget. 2018 Feb 1;9(13):11258-11267
pubmed: 29541411
Cell. 2009 Apr 3;137(1):47-59
pubmed: 19345186
Neuron. 1988 May;1(3):183-8
pubmed: 3272167
Neurobiol Dis. 2010 May;38(2):201-9
pubmed: 20079437
Nat Rev Immunol. 2015 Sep 15;15(9):545-58
pubmed: 26250739
Eur Neurol. 2014;72(3-4):132-41
pubmed: 25095894
Mol Neurobiol. 2019 Aug;56(8):5799-5814
pubmed: 30684217
Nat Rev Neurosci. 2007 Jan;8(1):21-32
pubmed: 17180160
Nat Genet. 2013 Nov;45(11):1353-60
pubmed: 24076602
Arch Neurol. 2011 Jul;68(7):879-88
pubmed: 21403007
Nucl Recept Signal. 2006;4:e002
pubmed: 16604165
Neurology. 2004 Apr 13;62(7):1231-2
pubmed: 15079038
Lancet. 2018 Apr 21;391(10130):1622-1636
pubmed: 29576504
Ann Neurol. 2004 Mar;55(3):410-7
pubmed: 14991819
Nat Genet. 2003 Jan;33(1):85-9
pubmed: 12496759
Science. 1997 Apr 11;276(5310):248-50
pubmed: 9092472
Lancet. 2008 Oct 25;372(9648):1502-17
pubmed: 18970977
J Neurosci. 2009 Dec 16;29(50):15923-32
pubmed: 20016108
N Engl J Med. 2006 Mar 2;354(9):942-55
pubmed: 16510748
Biochem Biophys Res Commun. 1994 Dec 30;205(3):1959-65
pubmed: 7811288
Exp Cell Res. 1999 Dec 15;253(2):737-46
pubmed: 10585298
J Invest Dermatol. 2008 Feb;128(2):300-10
pubmed: 17671512
PLoS One. 2010 Jan 29;5(1):e8962
pubmed: 20126412
J Neuroimmunol. 2006 May;174(1-2):108-18
pubmed: 16564577
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):4013-8
pubmed: 9520484
J Immunol. 2002 Mar 15;168(6):2979-87
pubmed: 11884470
PLoS One. 2013;8(2):e56595
pubmed: 23437182
Arch Neurol. 2003 May;60(5):722-5
pubmed: 12756136
J Neuroimmunol. 2014 Jul 15;272(1-2):99-102
pubmed: 24852325
Br J Pharmacol. 2011 Oct;164(4):1079-106
pubmed: 21371012
Front Immunol. 2018 Feb 20;9:311
pubmed: 29527211
J Investig Med. 2017 Jun;65(5):883-891
pubmed: 28130412
Eur J Neurol. 2019 Apr;26(4):667-672
pubmed: 30565812
PLoS One. 2014 Sep 29;9(9):e108791
pubmed: 25265488
Arterioscler Thromb Vasc Biol. 2006 Oct;26(10):2288-94
pubmed: 16873729
Bioorg Med Chem Lett. 2007 Jan 1;17(1):193-6
pubmed: 17035009
N Engl J Med. 1998 Jul 30;339(5):285-91
pubmed: 9682040
Nature. 2003 May 29;423(6939):555-60
pubmed: 12774125

Auteurs

Francesca Montarolo (F)

Neuroscience Institute Cavalieri Ottolenghi (NICO), University of Turin, Orbassano, 10043 Turin, Italy. francesca.montarolo@unito.it.
Neurobiology Unit, Neurology-CReSM (Regional Referring Center of Multiple Sclerosis), AOU San Luigi Gonzaga Orbassano, 10043 Turin, Italy. francesca.montarolo@unito.it.

Serena Martire (S)

Neuroscience Institute Cavalieri Ottolenghi (NICO), University of Turin, Orbassano, 10043 Turin, Italy. serena.martire@gmail.com.
Neurobiology Unit, Neurology-CReSM (Regional Referring Center of Multiple Sclerosis), AOU San Luigi Gonzaga Orbassano, 10043 Turin, Italy. serena.martire@gmail.com.

Simona Perga (S)

Neuroscience Institute Cavalieri Ottolenghi (NICO), University of Turin, Orbassano, 10043 Turin, Italy. simona.perga@unito.it.
Neurobiology Unit, Neurology-CReSM (Regional Referring Center of Multiple Sclerosis), AOU San Luigi Gonzaga Orbassano, 10043 Turin, Italy. simona.perga@unito.it.

Antonio Bertolotto (A)

Neuroscience Institute Cavalieri Ottolenghi (NICO), University of Turin, Orbassano, 10043 Turin, Italy. antonio.bertolotto@gmail.com.
Neurobiology Unit, Neurology-CReSM (Regional Referring Center of Multiple Sclerosis), AOU San Luigi Gonzaga Orbassano, 10043 Turin, Italy. antonio.bertolotto@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH